For as much as the sell-side seems to complain about Amgen (Nasdaq:AMGN), it doesn't seem to have resulted in the company missing out on the run-up in biotech and pharma names over the last 12 to 18 months. With uncertain risk from biosimilars and a pipeline that strikes many investors as lackluster, Amgen isn't the easiest name to like today, and the risk of the company overpaying for Onyx Pharmaceuticals (Nasdaq:ONXX) doesn't help. On balance, it's difficult to work up a lot of enthusiasm for Amgen at this price, but key clinical data in early 2014 could add some solid support to the stock.
Please continue here:
http://www.investopedia.com/stock-analysis/073113/does-amgen-deserve-be-part-biotech-bull-run-amgn-onxx-azn-teva.aspx
Investopedia: Does Amgen Deserve To Be Part Of The Biotech Bull Run?
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.